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the original work isObjective: To summarize published evidence on drug interactions between hormonal
contraceptives and antiretrovirals.
Design: Systematic review of the published literature.
Methods: We searched PubMed, POPLINE, and EMBASE for peer-reviewed publi-
cations of studies (in any language) from inception to 21 September 2015. We included
studies of women using hormonal contraceptives and antiretrovirals concurrently.
Outcomes of interest were effectiveness of either therapy, toxicity, or pharmacokinetics.
We used standard abstraction forms to summarize and assess strengths and weaknesses.
Results: Fifty reports from 46 studies were included. Most antiretrovirals whether used
for therapy or prevention, have limited interactions with hormonal contraceptive
methods, with the exception of efavirenz. Although depot medroxyprogesterone
acetate is not affected, limited data on implants and combined oral contraceptive pills
suggest that efavirenz-containing combination antiretroviral therapy may compromise
contraceptive effectiveness of these methods. However, implants remain very effective
despite such drug interactions. Antiretroviral plasma concentrations and effectiveness
are generally not affected by hormonal contraceptives.
Conclusion: Women taking antiretrovirals, for treatment or prevention, should not be
denied access to the full range of hormonal contraceptive options, but should be
counseled on the expected rates of unplanned pregnancy associated with all contra-
ceptive methods, in order to make their own informed choices.
Copyright Q 2017 The Author(s). Published by Wolters Kluwer Health, Inc.AIDS 2017, 31:917–952Keywords: antiretroviral therapy, contraceptive implant, depot
medroxyprogesterone acetate, HIV, hormonal contraception, systematic reviewIntroduction
Women living with HIV will likely take combination
antiretroviral therapy (cART) for much of their lives [1].
Those at high risk for HIV may also use antiretrovirals for
preexposure prophylaxis (PrEP). Contraceptive use
among women living with HIV or using antiretrovirals
for PrEP is critical, as unintended pregnancy and short
interpregnancy intervals can be associated with negative
health consequences for both mother and infant [2–4]., bUniversity of North Carolina Medical School,
nd, USA, dDivision of Pharmacology, Discipline
ica, eDivision of Reproductive Health, U.S. Cente
f Reproductive Health and Research, World He
o Dr Kavita Nanda, FHI360. 359 Blackwell Stre
i360.org
mber 2016; revised: 20 December 2016; accep
.0000000000001392
pyright Q 2017 The Author(s). Published by Wolters K
ns Attribution License 4.0 (CCBY), which permits unr
properly cited.Decreasing unintended pregnancies also reduces vertical
HIV transmission [5]. Hormonal contraceptives are
highly used worldwide, including in areas of high HIV
prevalence; they are also among the most effective
contraceptive methods [6,7]. Evidence-based guidance
for hormonal contraceptives use among women using
cARTor PrEP is needed to ensure access to a full range of
the best contraceptive methods, and therefore increase the
likelihood of achieving their reproductive life planning
goals.Chapel Hill, cJohns Hopkins University School of Medicine,
of Pharmaceutical Sciences, University of KwaZulu-Natal,
rs for Disease Control and Prevention, Atlanta, Georgia, USA,
alth Organization, Geneva, Switzerland.
et, Durham, NC 27709, USA.
ted: 21 December 2016.
luwer Health, Inc. This is an open access article distributed under
estricted use, distribution, and reproduction in any medium, provided
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Table 1. Steroids used in currently available contraceptive methods, their liver metabolism, and effects on liver enzymes.
Contraceptive steroid Abbreviation Contraceptive method type (s) Metabolism
Estrogens
Ethinyl estradiol EE COC, patch, ring Inhibits CYP2C19, CYP3A4, and CYP2B6
Induces UGTs
Metabolized by CYP3A4 and CYP 2C9 and UGT
Estradiol cypionate E2C CIC Inhibits CYP2C19, CYP3A4, and CYP2B6
Induces UGTs
Metabolized by CYP3A4 and CYP 2C9 and UGT
Estradiol valerate E2V COC Inhibits CYP2C19, CYP3A4, and CYP2B6
Induces UGTs
Metabolized by CYP3A4 and CYP 2C9 and UGT
Progestins
Ethynodiol diacetate EDA COCs Metabolized to norethindrone
Dienogest DNG COC Metabolized by CYP3A4
Nomegestrol acetate NOMAC COC Metabolized by CYP3A3, CYP3A4, and CYP2A6
Drospirenone DRSP COC Metabolized only to a minor extent, by CYP3A4
Gestodene GES COC Metabolized by CYP3A4
Norgestrel NG COC Metabolized by CYP3A4
Norgestimate NGM COC Metabolized by CYP3A4
Desogestrel DSG COC, POP Metabolized by CYP2C9 and CYP3A4
Norethindrone, norethindrone acetate NET COC, POI, POP Metabolized by CYP3A4
Norethisterone enanthate
Levonorgestrel LNG COC, implant, IUD, ECP Metabolized by CYP3A4
Norelgestromin NGMN Patch Metabolized by CYP3A4
Etonogestrel ENG Ring, implant Metabolized by CYP3A4
Medroxyprogesterone acetate MPA CIC, POI Metabolized by CYP3A4
Data from USFDA prescribing information, and review articles summarizing published literature. CIC, combined injectable contraceptives; COC,
combined oral contraceptive; CYP, cytochrome P450 isozyme; ECP, emergency contraceptive pill; IUD, intrauterine device; MPA, medroxy-
progesterone acetate; POI, progestin-only injectable; POP, progestin-only pill; UGT, uridine diphosphate glucuronosyltransferase.Concurrent use of hormonal contraceptives and anti-
retrovirals can lead to drug interactions, predominantly
due to effects on liver metabolism (Tables 1 and 2). In the
liver, cytochrome P450 (CYP) enzymes catalyze many
important reactions, with the most significant for
contraceptive metabolism being CYP3A4, which is also
expressed in the intestines [8,9]. Antiretrovirals include
different classes of drug (Table 2), including nonnucleo-
side reverse transcriptase inhibitors (NNRTIs), nucleo-
side analogue reverse transcriptase inhibitors or
nucleotide analogue reverse transcriptase inhibitor
(NRTIs), protease inhibitors, fusion inhibitors, and
integrase inhibitors. The NNRTIs and integrase inhibi-
tors are generally not substrates, inhibitors, nor inducers
of cytochrome P450 enzymes [10]. In contrast, both
protease inhibitors and NNRTIs are metabolized by
CYP3A4 and also inhibit or induce this enzyme, resulting
in increases or decreases in the concentration of
concomitantly administered drugs [10].
Such interactions could lead to decreased contraceptive
effectiveness (increasing risk of unintended pregnancy),
decreased cART effectiveness (associated with resistance
and/or HIV disease progression), decreased efficacy of
PrEP (increasing risk of HIV acquisition), or increased
antiretroviral or contraceptive toxicity. Based on theor-
etical concerns and limited data, women using cART are
sometimes offered fewer contraceptive choices than their
HIV-negative peers [11]. The objective of this review was
to systematically examine published evidence on drug
interactions between hormonal contraceptives andantiretrovirals, in order to contribute to improved clinical
and policy decision-making.Methods
We followed the PRISMA and MOOSE guidelines for
conducting the review and reporting the results [12,13].
We searched PubMed, POPLINE, and EMBASE from
database inception to 21 September 2015 for studies of
hormonal contraceptive and antiretroviral drug inter-
actions (Supplement 1, http://links.lww.com/QAD/
B36). We also hand-searched reference lists of published
studies, and contacted topic experts.
Study selection
We included published studies of women using hormonal
contraceptives (Table 1), including combined oral
contraceptives (COCs), progestin-only pills (POPs),
emergency contraceptive pills (ECPs), injectables, vaginal
rings, patches, or implants. Studies included women who
were either HIV-positive, HIV-negative but at risk of
HIV, or healthy, who concurrently used cART, PrEP, or
single antiretrovirals and hormonal contraceptives. We
included studies reporting on women taking oral
contraceptives where the type of oral contraceptive was
not specified. We excluded studies evaluating women on
cART without comparisons by contraceptive use, those
evaluating only genital HIV viral load, and those
Contraceptive antiretroviral drug interactions Nanda et al. 919
Table 2. Antiretrovirals included in the review, their liver metabolism, and effects on liver enzymes.
Generic name Liver metabolism
NNRTIs
Efavirenz (EFV) Induces CYP3A4, CYP2B6, and UGTs
Metabolized by CYP2B6 and CYP3A
Etravirine (ETR) Induces CYP3A and inhibits CYP2C9, CYP2C19
Metabolized by CYP3A, CYP2C9, and CYP2C19
Nevirapine (NVP) Induces CYP3A and CYP2B6
Metabolized by CYP3A, CYP2B6, and UGTs
Rilpivirine (RPV) At higher doses (>3 approved 25 mg dose), induces CYP3A4
Metabolized by CYP3A4, CYP2C19, CYP1A2, and CYP2C
Delavirdine (DLV) Inhibits CYP3A, CYP3A4, CYP2C9, CYP2D6, and CYP2C19
Metabolized by CYP3A and CYP2D6
Fosdevirine/GSK GSK2248761a Weak inhibitor of CYP3A4 and CYP2D6
Metabolized by CYP3A4?
NRTIs
Zidovudine (ZDV) or azidothymidine (AZT) Does not affect liver enzymes
Metabolized by UGTs
Abacavir (ABC) Does not affect liver enzymes
Metabolized by alcohol dehydrogenase and UGTs
Tenofovir disoproxil fumarate (TDF) Does not affect liver enzymes
Minimal liver metabolism; mostly eliminated unchanged in urine
Emtricitabine (FTC) Does not affect liver enzymes
Minimal liver metabolism; mostly eliminated unchanged in urine
Didanosine (DDI) Does not affect liver enzymes
Minimal liver metabolism; mostly eliminated unchanged in urine
Lamivudine (3TC) Does not affect liver enzymes
Minimal liver metabolism; mostly eliminated unchanged in urine
Stavudine (d4T) Does not affect liver enzymes
Minimal liver metabolism; mostly eliminated unchanged in urine
PIs
Ritonavir (RTV) Induces and inhibits CYP3A
Induces CYP1A2, CYP2C9, CYP2C19, CYP2B6, and UGTs
Inhibits CYP2D6
Metabolized by CYP3A, CYP2D6
Atazanavir (ATV) Inhibits CYP3A and UGT1A1, and weak inhibitor of CYP2C8
Mostly metabolized by CYP3A4; other pathways include UGTs
Darunavir (DRV) Co-administered with ritonavir, inhibits CYP3A and CYP2D6
Mostly metabolized by CYP3A
Fosamprenavir (FOS-APV) Amprenavir, the active metabolite, induces and inhibits CYP3A4
Metabolized by CYP3A4
Saquinavir (SQV) Co-administered with ritonavir, inhibits CYP3A
Metabolized by CYP3A
Tipranavir (TPV) Co-administered with ritonavir, inhibits CYP3A and CYP2D6
Induces CYP1A2 and CYP2C19 at steady state
Metabolized by CYP3A
Indinavir (IDV) Inhibits CYP3A4
Weak inhibitor of CYP2D6
Metabolized by CYP3A4
Nelfinavir (NFV) Inhibits CYP3A4
Metabolized by CYP3A, CYP2C19
CCR5 inhibitors
Maraviroc (MVC) Inhibits CYP2D6 at higher doses
Metabolized by CYP3A
Vicriviroc (VCV)a Does not affect liver enzymes
Metabolized by CYP3A
Fusion inhibitors
Enfuvirtide (ENF) Does not affect liver enzymes
Catabolized to constituent amino acids
Integrase inhibitors
Dolutegravir (DTG) Not an inducer or inhibitor of CYP enzymes
Metabolized by UGTs and CYP3A
Elvitegravir (EVG) Inducer of CYP2C9
Metabolized by CYP3A4
Raltegravir (RAL) Not an inducer or inhibitor of CYP enzymes
Metabolized by UGTs
Pharmacokinetic enhancers
Cobicistat (COBI) Inhibits CYP3A, CYP2D6
Metabolized by CYP3A
Data from prescribing information, http://medicine.iupui.edu/clinpharm/ddis/main-table, and https://aidsinfo.nih.gov/drugs. CYP, cytochrome
P450 isozyme; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside or nucleotide reverse-transcriptase inhibitor; PI, protease
inhibitor; UGT, uridine diphosphate glucuronosyltransferase.
aDevelopment halted due to toxicity or lack of efficacy.
920 AIDS 2017, Vol 31 No 7evaluating only hormonal intrauterine devices (IUDs).
We also excluded case or case-series reports, cross-
sectional studies, reviews, editorials, and letters.
Outcomes of interest were clinical and pharmacokinetic
measures of the contraceptive and the antiretroviral.
Clinical outcomes included measures of contraceptive,
cART, or PrEP effectiveness, and combined toxicity.
Contraceptive effectiveness measures of interest were
pregnancy or surrogate measures of pregnancy risk,
including ovulation, ovarian activity, or cervical mucus.
Because no studies reported on true ovulation as
documented by ultrasound, we included studies using
serum progesterone alone as a marker of presumed
ovulation. For cART effectiveness, we included studies
that reported markers of HIV disease progression such as
CD4þ cell count or HIV viral load, need for change in
cART regimen, or death; for PrEP effectiveness, the
relevant outcome was HIV prevention. Pharmacokinetic
endpoints were plasma drug concentrations over time, as
well as the area under the concentration–time curve
(AUC), half-life (t1/2), minimum (Cmin; trough) and
maximum (Cmax; peak) concentrations, for both contra-
ceptive steroids and antiretrovirals.
Data abstraction and management
After screening and removal of duplicates, we abstracted
relevant data from each included report using a
predesigned form. Two authors independently reviewed
selected manuscripts, with differences resolved by
consensus.
We described strengths, weaknesses, and funding source
for each included study (Tables 3 and 4) [14–65], but did
not do formal quality assessment because no formal
evidence grading system exists for pharmacokinetic
studies.Results
Our search identified 1570 records. Fifty published
reports from 46 individual studies met the inclusion
criteria (Fig. 1, Tables 3 and 4). Four reports were
secondary analyses or subsets of the primary studies and
are included with the primary study in the tables [14–17].
The results are presented by outcome assessed, focusing
first on the most important clinical outcomes (contra-
ceptive effectiveness, antiretroviral effectiveness, toxicity
associated with combined administration), then the
pharmacokinetic data (for contraceptives and antiretro-
virals), in each case by antiretroviral class and by
contraceptive method.
Contraceptive effectiveness
Although pregnancy is the most relevant outcome, few
large studies were designed to investigate contraceptiveeffectiveness. Several secondary analyses helped fill this
gap, particularly for women using nevirapine-containing
or efavirenz-containing cART. Although some small
pharmacokinetic studies of healthy women report on
pregnancy, women were generally required to use
additional contraception; these studies are included in
Table 3 but not summarized here.
Nonnucleoside reverse transcriptase inhibitors
Fourteen reports from clinical trials and six secondary
analyses described contraceptive effectiveness measures
among women using NNRTIs and hormonal contra-
ceptives (Table 3).
Oral contraceptives
Two clinical trials of women using cART and oral
contraceptives [18,19], six secondary analyses [20–25]
and five pharmacokinetic trials (mostly in healthy women
using single antiretrovirals with COCs) [26–30],
evaluated pregnancy or ovulation. No pregnancies were
found to be associated with nevirapine or efavirenz in the
prospective clinical trials.
Pregnancy rates and ovulation rates did not differ between
HIV-positive women taking COCs and nevirapine-
containing cARTand those not yet taking cART [18]. In
a small trial of women using COCs with efavirenz-
containing cART, three women ovulated (out of 25) but
no pregnancies were reported [19]. Five small pharma-
cokinetic trials of NNRTIs and COCs also demonstrated
no ovulation among study participants [26–30].
In large cohort studies, pregnancy rates were slightly
higher among women taking efavirenz-containing cART
(11–15/100 woman-years) compared with women
taking oral contraceptive and nevirapine-containing
cART or no cART (pregnancy rates 6–11/100
woman-years) [24,25]. Notably the reported pregnancy
rates in the large cohort studies are still lower than an
expected pregnancy rate of 40 per 100 woman-years
among women not using any modern contraceptive and
trying to prevent pregnancy.
Other retrospective cohort studies reported pregnancy
rates among oral contraceptive users ranging from 2.6 to
5.8 per 100 woman-years (most, but not all, women were
using nevirapine) [20,21].
Depot medroxyprogesterone acetate
In two pharmacokinetic studies, women using depot
medroxyprogesterone acetate (DMPA) remained anovu-
latory when using cART containing either efavirenz or
nevirapine [14,31,32]. Five cohort studies also presented
pregnancy rates with injectables among cART users. In
the largest, pregnancy rates ranged from 8 to 10 per 100
woman-years for injectable users, with higher rates in
efavirenz users and those not on cART compared with
pregnancy rates in those using nevirapine [24]. Another



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Contraceptive antiretroviral drug interactions Nanda et al. 943found women using DMPA had pregnancy rates from 3 to
5 per 100 woman-years, with lower rates among users of
nevirapine and efavirenz compared with no cART [25].
Two additional studies reported pregnancy rates from 1.8
to 4.2 per 100 woman-years among DMPA users taking
various antiretrovirals (primarily nevirapine) [20,21].
Implants
Pregnancy rates among users of cART and contraceptive
implants differed by whether the implant contained
levonorgestrel or etonogestrel, and whether women were
taking efavirenz or nevirapine. Pregnancy rates were
higher among women using the levonorgestrel implant
concomitantly with efavirenz. Two prospective studies
(N¼ 79 and N¼ 45) reported no pregnancies through 3
years and 6 months, respectively, among women using
etonogestrel implants and NNRTI-containing cART
[33,34], although the second study found that women
taking efavirenz-containing cART had a 2.8% presumed
ovulation rate over 6 months. In a small pharmacokinetic
study of women using levonorgestrel implants and cART
containing efavirenz or nevirapine, three pregnancies
(3/20; 15%) occurred within 48 weeks, all in women
taking efavirenz [35]. Similar findings were seen in a large
retrospective study, where 15 of 121 (12.4%) women
using levonorgestrel implants and efavirenz-containing
cART became pregnant, at a mean duration of
16.4 months; no pregnancies occurred among women
taking nevirapine-containing cART [36].
Two secondary analyses described pregnancy rates with
implant use in women using efavirenz-containing or
nevirapine-containing cART [24,25]. In the first,
pregnancy rates for users of efavirenz, nevirapine, and
no cARTwere 5.5, 2.3, and 3.4 per 100 woman-years for
etonogestrel implant users, and 7.1, 1.9, and 3.3 per 100
woman-years for levonorgestrel implant users, respect-
ively [24]. In the second, pregnancy rates per 100 woman-
years were 1.4 for unspecified implant users not taking
cART, 0 for nevirapine users, and 6 for women taking
efavirenz [25].
Protease inhibitors
Seven small pharmacokinetic trials described contra-
ceptive effectiveness measures among women using
protease inhibitors and hormonal contraceptives (Table
3) [14,16,31,34,37–39].
Combined oral contraceptives/patches
Co-administration of darunavir/ritonavir with COCs
resulted in no ovulation [38]. Similarly, coadministration
of lopinavir/ritonavir containing cART in women using
a contraceptive patch also found no ovulations [37].
Progestin-only pills
One report showed that oral norethindrone thickened
cervical mucus and led to similar mucus scores in womenusing protease inhibitor-containing cART compared
with those taking NRTIs alone [16].
Depot medroxyprogesterone acetate
Reports of women using lopinavir/ritonavir-containing
or nelfinavir-containing cART with DMPA found that
no women ovulated [14,31,39].
Implants
No ovulations nor pregnancies were reported in a
pharmacokinetic study of etonogestrel implant users
taking lopinavir/ritonavir-containing cART [34].
Nucleoside/nucleotide reverse transcriptase
inhibitors
Analyses of two large trials of hormonal contraceptives
and NRTIs used for PrEP found that use of tenofovir/
emtricitabine did not affect pregnancy rates among users
of COCs, injectables, or implants [40,41].
Integrase inhibitors
A small pharmacokinetic study of dolutegravir with
COCs resulted in no ovulations [42].
Antiretroviral effectiveness
Eight reports evaluated the effects of hormonal contra-
ceptive use on the effectiveness of NNRTI-containing or
protease inhibitor-containing cART, and found no effects
on death, CD4þ cell count, or plasma viral load with
concurrent use of DMPA, levonorgestrel implants, or oral
contraceptives [14,43–49]. Use of DMPA also did not
affect the efficacy of PrEP [50].
Toxicity of combined administration
Studies among healthy women using hormonal contra-
ceptives concurrently with single antiretrovirals, or HIV-
positive women using cART, generally reported no
difference in adverse events of concurrent treatment
compared with use of either hormonal contraceptives or
antiretrovirals alone (Table 3). One HIV prevention trial
evaluated pharmacodynamic interactions between teno-
fovir-containing PrEP with oral contraceptives or
DMPA, and found that bone mineral density was not
significantly decreased [51].
Contraceptive pharmacokinetics
Thirty-two reports include contraceptive pharmacoki-
netic measures among women using antiretrovirals and
hormonal contraceptives (Table 4).
Nonnucleoside reverse transcriptase inhibitors
Contraceptive pharmacokinetics among women using
NNRTIs and hormonal contraceptives were described in
11 studies (Table 4) [15,26–32,34,52,53].
Combined oral contraceptives
Two studies evaluated efavirenz with COCs: one in
women taking only efavirenz, and one in women taking
944 AIDS 2017, Vol 31 No 7





identified through other 
sources
(n = 21)
Records after duplicates removed 
(n = 1570)
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Full-text publications 
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N = 50 publications representing 46
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Records excluded after 
reviewing abstracts
(n = 1518)
Fig. 1. Flow diagram of publication selection for inclusion
into the review.efavirenz-containing cART [15,26]. Ethinyl estradiol
concentrations were not significantly changed, but
progestin levels decreased by approximately 60%.
Three studies reported the effect of nevirapine on COC
pharmacokinetics. Ethinyl estradiol levels varied from
being unchanged to being approximately 30–60% lower
[15,30,53]. Progestin levels were not significantly
affected.
Studies of etravirine and rilpivirine in women taking
COCs found minimal effects [27,28]. Similarly, a study of
fosdevirine (the development of which was discontinued
due to toxicity) found no effect on hormone levels in
COC users [29].
Depot medroxyprogesterone acetate
Two studies evaluated the effect of NNRTIs on DMPA,
and found no difference in medroxyprogesterone acetate
pharmacokinetics through 12 weeks with concurrent use
of either efavirenz-containing or nevirapine-containing
cART [31,32].
Implants
A study of women using etonogestrel implants found 54–
70% lower etonogestrel levels among women takingefavirenz-containing cART compared with women
taking no cART [34].
Emergency contraceptive pills
One study in healthy women showed that levonorgestrel
levels were 56% lower in ECP users after use of efavirenz
[52].
Protease Inhibitors
Ten reports described contraceptive pharmacokinetics
among women using protease inhibitors and hormonal
contraceptives (Table 3) [17,31,34,37–39,54–57].
Combined oral contraceptives/Patch
Two studies examining concurrent use of ritonavir and
COCs found decreased ethinyl estradiol levels, whereas
progestin levels were unaffected [54,57]. Another study
showed decreased ethinyl estradiol levels, but increased
progestin levels, when COCs were used with atazanavir/
ritonavir [55]. Similar findings were reported with
lopinavir/ritonavir-containing cART and the contra-
ceptive patch [37]. This study also reported lower ethinyl
estradiol levels with concurrent use of a single COC pill,
but progestin levels were not evaluated. Only darunavir/
ritonavir was associated with significantly lower ethinyl
estradiol levels as well as slightly lower norethindrone
levels [38].
Progestin-only pills
In women receiving protease inhibitor-containing cART,
norethindrone levels were higher compared with controls
[56]. A subanalysis restricted to women using ritonavir-
boosted atazanavir confirmed this finding [17].
Depot medroxyprogesterone acetate
One study showed significantly increased medroxypro-
gesterone acetate concentrations, compared with histori-
cal controls, in women using DMPA and lopinavir/
ritonavir-containing cART [39].
Implants
A study evaluating the effect of cART on the
pharmacokinetics of the etonogestrel implant found
women using lopinavir/ritonavir-containing cART had
etonogestrel levels approximately 50% higher than
women not taking cART [34].
Nucleoside/nucleotide reverse transcriptase
inhibitors
Two studies evaluating NRTIs used for PrEP with COCs
or levonorgestrel implants showed no change in hormone
levels [58,59].
Chemokine receptor 5 antagonists
Two studies showed that neither maraviroc nor vicriviroc
impacted hormone levels when used concurrently with
COCs [57,60].
Contraceptive antiretroviral drug interactions Nanda et al. 945Integrase inhibitors
In two studies, concurrent use of COCs and raltegravir
led to small increases in progestin exposure [61], but
dolutegravir had no impact on hormone levels [42].
Antiretroviral pharmacokinetics
Fifteen studies described antiretroviral pharmacokinetics
among women using antiretrovirals and hormonal
contraceptives; most were among healthy women and
compared drug concentrations to historical controls
(Table 4) [19,26,27,31,37–39,53–55,60,62–65].
Nonnucleoside reverse transcriptase inhibitors
Three studies evaluated the impact of COCs on the
pharmacokinetics of efavirenz [19,26,62]. Among
women using COCs and efavirenz alone, concentrations
were similar to historical controls [26]. However, in a trial
of women on efavirenz-containing cART, use of COCs
led to efavirenz concentrations lower than historical
controls [19]. Another analysis of women taking
efavirenz-containing cART found no difference in
efavirenz concentrations between hormonal contracep-
tive users and nonusers [62].
Three studies evaluated the impact of COCs on
nevirapine levels. In two reports of women using
nevirapine-containing cART, nevirapine levels were
not significantly different in women using COCs
[19,53]. Time to undetectable nevirapine levels was
longer in women receiving single-dose nevirapine and
using COCs [63]. Another study found rilpivirine levels
in COC users to be similar to historical controls [27].
Among women on various cART regimens, nevirapine
levels were slightly higher after administration of DMPA,
but no changes in efavirenz levels were noted [31].
Protease inhibitors
Four studies investigated the effects of COCs on the
pharmacokinetics of protease inhibitors [38,54,55,64].
Levels of saquinavir were not affected by COC use, but
atazanavir levels were slightly increased [55,64]. Co-
administration with COCs resulted in darunavir and
ritonavir levels comparable to those in historical controls
[38,54].
Co-administration of the contraceptive patch with
lopinavir/ritonavir-containing cART resulted in slightly
decreased levels of both protease inhibitors compared
with historical controls [37], whereas DMPA had no




One study found no effect of hormonal contraceptives
(COCs and DMPA) on zidovudine plasma or intracellular
pharmacokinetics [65].Chemokine receptor 5 antagonists
When maraviroc was taken with COCs, levels were
similar to those seen in historical controls [60].Discussion
Few of the 50 reports included in this review provided
relevant data that can be applied to clinical practice with
certainty (Table 5). The most significant interactions with
hormonal contraceptives occurred in women using
cART-containing NNRTIs, particularly efavirenz. How-
ever, even in these studies, the outcomes reported were
often pharmacokinetic rather than clinical, involved small
populations, which limited study power, or were derived
retrospectively from secondary analyses of existing
cohorts.
The most important outcome for contraceptive drug
interactions is method failure resulting in pregnancy, but
few studies reported this outcome (Table 5). Changes in
contraceptive hormone levels do not necessarily translate
into reduced efficacy or increased toxicity, as levels vary
greatly within and between individuals and populations
[66,67]. Further, the contraceptive threshold, or mini-
mum steroid hormone level required to maintain
contraceptive effectiveness, is difficult to determine
[68,69]. However, when pharmacokinetic data show
no or minimal changes, clinical effects are unlikely.
Ovulation is used in many drug–drug interaction studies
to indicate risk of pregnancy, but ovulation is also a
surrogate marker. The occurrence of ovulation does not
always result in pregnancy. For example, many women
ovulate during levonorgestrel implant use, yet contra-
ceptive effectiveness remains high [70]. Additionally, no
included studies evaluated true ovulation; rather,
ovulation was presumed based on serum progesterone
measurements alone, which can be inaccurate [70].
The most clinically significant drug–drug interactions
identified in our systematic review were reported in
women using efavirenz-containing cART and COCs or
progestin-containing subdermal implants. Although
studies show DMPA is not impacted by efavirenz use,
studies of women using efavirenz and contraceptive
implants reported pregnancy rates ranging from 5 to 15
per 100 woman-years, and COC users taking efavirenz
had pregnancy rates ranging from 13 to 15 per 100
woman-years [24,25,35]. For COCs, because contra-
ceptive effectiveness relies on user adherence, potential
additional reductions in effectiveness from a drug
interaction, if confirmed, are concerning. Conversely,
studies that reported on women using contraceptives with
nevirapine-containing cART were generally reassuring.
None of the studies that enrolled women using a number
of different hormonal contraceptives with nevirapine




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Contraceptive antiretroviral drug interactions Nanda et al. 949reported increases in pregnancy or ovulation rates
[18,19,21,24,25,30,35,36,45].
The many other studies included in this review that
evaluated hormonal contraceptives and antiretrovirals
other than efavirenz reported no results that should
change clinical practice. Antiretrovirals used in PrEP do
not affect hormonal contraceptive effectiveness. Con-
current use of protease inhibitors with COCs does not
alter contraceptive effectiveness despite the observed
decreased ethinyl estradiol plasma levels found, as the
progestin component is primarily responsible for contra-
ceptive effectiveness. Minimal to no changes in progestin
levels were reported in multiple studies of concurrent
protease inhibitor and hormonal contraceptive use.
Although concomitant use of a few protease inhibitors
led to increased progestin levels in some studies, these
changes are unlikely to impact safety given the variable
doses and wide safety margin of contraceptive progestins.
Despite the small number of reports in our review, studies
were also reassuring with regard to the effect of hormonal
contraceptives on cART or PrEP effectiveness, or
antiretroviral pharmacokinetics. Pharmacokinetic studies
were limited because they either only reported anti-
retroviral pharmacokinetics compared with historical
controls or presented data from healthy women taking
single antiretrovirals.
Concurrent antiretroviral and hormonal contraceptive
use also does not appear to lead to increased toxicity,
though most studies were of short duration (1–28 days).
Short-term pharmacokinetic studies may not accurately
reflect adverse effects that may occur during use of long-
term cART or PrEP with hormonal contraceptives. The
only study to evaluate long-term toxicity showed little
impact of concurrent use of DMPA and tenofovir on
bone mineral density over 1 year [51]. Pharmacokinetic
effects may also be time-dependent, further limiting the
utility of short-term evaluations.
Strengths of our review included a comprehensive search
strategy, systematic review of study inclusion by all
authors, and dual data abstraction. Limitations are
generally due to lack of studies evaluating relevant
clinical outcomes. In addition, few studies are available
regarding whether implants containing levonorgestrel or
etonogestrel have different contraceptive effectiveness
when used with efavirenz. Furthermore, with both
implants, it is possible that interactions with enzyme
inducers such as efavirenz are time-dependent, because
hormone levels decrease over time after implantation
[71]. Other data gaps are whether injectable contra-
ceptives other than intramuscular DMPA, such as the
lower-dose subcutaneous DMPA or injectable norethis-
terone enanthate, might be susceptible to drug inter-
actions. Questions also remain regarding any impact of
lower-dose efavirenz regimens [72] on hormonalcontraceptive effectiveness, which cannot be predicted.
Another limitation is that intracellular antiretroviral
concentrations are likely a better predictor of clinical
effectiveness than plasma levels, but pharmacokinetic
studies only reported the latter. Finally, women on cART
may also take other drugs that can alter liver metabolism,
such as rifampin, and the combined effect of multiple
enzyme-inducing medications on contraceptive hor-
mone levels remains poorly characterized.
Our review highlights the dearth of studies designed to
provide meaningful clinical data to guide contraceptive
choices for HIV-positive women taking cART. Studies
should be designed to report clinical outcomes such as
pregnancy and HIV disease progression during long-term
administration. Currently, incomplete data are being used
to limit contraceptive choices for HIV-positive women.
In the absence of well conducted prospective clinical
trials, data from pharmacokinetic studies and secondary
analyses have been used to make clinical judgments on
medication effectiveness and inform contraceptive policy.
For example, in October 2014 the South African
authorities recommended that women using efavirenz
or other enzyme-inducing drugs should not use
etonogestrel implants [11]. In May 2016, the European
Medicines Agency recommended that women taking
hepatic enzyme inducing drugs, including efavirenz, be
offered double doses of oral levonorgestrel for postcoital
emergency contraception [73]. When such guidance is
developed, the absolute risk of pregnancy should be
considered and addressed in the guidance publications, as
well as other considerations such as availability and
contraceptive effectiveness of the alternatives proposed.
Even if a particular contraceptive method is potentially
less effective than usual in a woman using a concomitant
antiretroviral, it may still be more effective than many
alternative contraceptive methods [74]. Although non-
hormonal methods such as copper IUDs are not affected
by drug interactions, their use remains very low in many
settings worldwide, and efforts to increase IUD use have
had limited success [7]. If access to implants is restricted,
in many settings DMPA would be the primary option
available to women, virtually eliminating woman-
centered decision making.
In summary, current published data do not support
limiting women’s access to any hormonal contraceptives.
Women taking antiretrovirals for HIV treatment (in the
form of cART) or prevention (in the form of PrEP)
should have access to the full range of hormonal
contraceptive options, and be enabled to make informed
decisions about their options. Contraceptive efficacy is
only one of many factors that an individual may consider
when choosing a contraceptive method, and some
women who are motivated to use the etonogestrel
implant may wish to do so even if there is concern for
decreased efficacy when used with efavirenz. National or
regional restrictions on contraceptive method access,
950 AIDS 2017, Vol 31 No 7while well intentioned, supersede women’s personal
decisions, which may actually increase risk of unintended
pregnancy if remaining contraceptive options are unac-
ceptable or inaccessible. More well designed prospective
studies are needed to examine potential drug interactions
between antiretrovirals and all contraceptive methods, to
better inform guidelines and counseling for the more than
16 million women living with HIV.Acknowledgements
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